← Leaderboards
Joshua Nicholas Farr
Mayo Clinic Rochester
$2,801,236
Attributed
$3,010,756
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $587.1K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,010,756 · 3
By mechanism
R01$1,951,546 · 1
K01$640,170 · 1
R21$419,040 · 1
Top collaborators
- Sundeep Khosla2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- James L. Kirkland$27,302,366
- Sundeep Khosla$91,221,003
- Paul D. Robbins$18,718,334
- Latonya J Hickson$2,371,961
- Darren Baker$10,907,779
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingCellsBoneCdkn2a GeneInnovationTransgenic Suicide GeneSkeletalApoptosisPharmaceutical PreparationsOsteocytesCell AgingSenescenceRisk FactorsAgingGeneticFracturePreventMolecularAgedInflammatoryBone RemodelingInsightFunctional DisorderIn Vitro
Grant awards (13)
Targeting Cellular Senescence and RAGE in Type 2 Diabetes$378,551
R01 · FY2025 · DK · contact PI
Targeting Cellular Senescence and RAGE in Type 2 Diabetes$355,756
R01 · FY2024 · DK · contact PI
Targeting Cellular Senescence and RAGE in Type 2 Diabetes$24,739
R01 · FY2024 · DK · contact PI
Targeting Cellular Senescence and RAGE in Type 2 Diabetes$397,500
R01 · FY2023 · DK · contact PI
Targeting Cellular Senescence and RAGE in Type 2 Diabetes$397,500
R01 · FY2022 · DK · contact PI
Targeting Cellular Senescence and RAGE in Type 2 Diabetes$397,500
R01 · FY2021 · DK · contact PI
Targeting cellular senescence with senolytics to improve skeletal health in older humans$189,645
R21 · FY2021 · AG · contact PI
Targeting cellular senescence with senolytics to improve skeletal health in older humans$229,395
R21 · FY2020 · AG · contact PI
The Role of Cellular Senescence in Mediating Age-Related Bone Loss$128,034
K01 · FY2020 · AR · contact PI
The Role of Cellular Senescence in Mediating Age-Related Bone Loss$128,034
K01 · FY2019 · AR · contact PI
The Role of Cellular Senescence in Mediating Age-Related Bone Loss$128,034
K01 · FY2018 · AR · contact PI
The Role of Cellular Senescence in Mediating Age-Related Bone Loss$128,034
K01 · FY2017 · AR · contact PI
The Role of Cellular Senescence in Mediating Age-Related Bone Loss$128,034
K01 · FY2016 · AR · contact PI